Top Page
Percheron Therapeutics
(Sydney:PER)
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Percheron Therapeutics Business Overview & Revenue Model
Percheron Therapeutics Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.97K | -67.98K | -79.42K | -95.20K | -89.22K | -103.32K |
| EBITDA | -10.94M | -16.27M | -11.84M | -13.25M | -7.52M | -8.58M |
| Net Income | -9.49M | -14.92M | -11.92M | -11.38M | -5.81M | -8.06M |
Balance Sheet | ||||||
| Total Assets | 7.90M | 12.44M | 14.53M | 12.84M | 22.44M | 7.00M |
| Cash, Cash Equivalents and Short-Term Investments | 4.46M | 10.17M | 11.87M | 10.97M | 19.23M | 6.02M |
| Total Debt | 10.68K | 25.86K | 39.87K | 142.10K | 227.40K | 306.85K |
| Total Liabilities | 763.70K | 2.43M | 5.17M | 2.87M | 1.30M | 1.27M |
| Stockholders Equity | 7.14M | 10.00M | 9.36M | 9.98M | 21.14M | 5.73M |
Cash Flow | ||||||
| Free Cash Flow | -9.78M | -15.65M | -10.12M | -8.18M | -7.81M | -5.84M |
| Operating Cash Flow | -9.78M | -15.64M | -10.12M | -8.15M | -7.81M | -5.83M |
| Investing Cash Flow | -3.08M | -7.24K | -3.61K | -29.29K | -3.91K | -8.35K |
| Financing Cash Flow | -70.82K | 13.95M | 11.02M | -85.30K | 21.02M | 7.80M |
Percheron Therapeutics Peers Comparison
Percheron Therapeutics Corporate Events
Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer, allowing eligible shareholders to subscribe for two new shares for every five existing shares at an issue price of $0.005, with one free attaching option for every two new shares subscribed. The company will also run a shortfall offer on the same terms for any unsubscribed securities, with directors retaining discretion to scale back allocations, and option holders must first exercise their options by the record date if they wish to participate, potentially broadening the shareholder base and strengthening the company’s capital position.
The entitlement offer includes new options expiring two years from issue with an exercise price of $0.01, providing additional potential future funding if exercised. By structuring the raise with both an entitlement and shortfall offer, Percheron aims to maximise subscription uptake while offering existing investors the opportunity to increase their holdings and influence, which may impact control dynamics and liquidity in the company’s shares over time.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has notified the ASX of a proposed issue of up to 50 million unquoted options as part of a placement or similar capital initiative. The options will be exercisable at $0.01 per share and will expire two years from the date of issue, with an expected issue date of 15 April 2026.
The new options, which will constitute a separate class of unquoted securities, provide the company with an additional capital-raising and incentive mechanism for investors or stakeholders. This move may strengthen Percheron Therapeutics’ financial flexibility as it pursues its development activities and seeks to enhance its position in the biopharmaceutical sector.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has announced a proposed non-renounceable pro rata offer to existing shareholders, comprising up to 434,975,053 new fully paid ordinary shares and 217,487,526 unquoted options exercisable at A$0.01 within two years of issue. The timetable sets an ex-date of 19 March 2026, a record date of 20 March 2026, offer closing on 8 April 2026 and an issue date of 15 April 2026, signaling a significant capital-raising move that could materially expand the company’s equity base and provide additional funding flexibility.
The structure of the offer, including the attached low-priced options, is likely designed to encourage shareholder participation while potentially increasing future dilution if options are exercised. By opting for a standard non-renounceable pro rata issue, Percheron aims to give existing investors priority access to the new securities, which may help support its balance sheet and advance its therapeutic programs, though it concentrates the opportunity and associated risk within the current shareholder base.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has updated the timetable for its previously announced non-renounceable entitlement offer, which aims to raise up to approximately $2.2 million. The revised schedule adjusts the ex date and record date, and sets out key milestones including dispatch of offer documents on 24 March 2026, a closing date of 8 April 2026, and anticipated quotation of new shares on 16 April 2026, with all dates remaining indicative and subject to change under ASX rules.
The entitlement offer’s proceeds are expected to support Percheron’s ongoing operations and its pipeline of oncology and rare disease therapies, including further clinical development of its lead antibody program HMBD-002. The capital raise and updated timetable underscore the company’s efforts to secure funding ahead of planned 2026 clinical trials, which may influence its competitive position in the immuno-oncology sector and be relevant for existing shareholders assessing participation in the offer.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics Limited has released a prospectus for a two-for-five pro rata non-renounceable rights offer, allowing eligible shareholders to subscribe for new shares at $0.005 each, with one new option issued for every two new shares taken up. The document also outlines a shortfall offer and a joint lead manager options offer, with the capital raising framed as speculative and intended to support the company’s future activities, underscoring both the funding needs and risk profile facing existing and prospective investors.
The offers are scheduled to close on 8 April 2026 at 5:00 p.m. AEST, with the company reserving the right to vary the timetable, placing a time-bound decision on shareholders considering participation. By structuring the raising as a pro rata rights issue with additional options, Percheron seeks to balance shareholder dilution with participation opportunities while signalling its continued reliance on equity markets to finance its growth and development plans.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has launched a 2-for-5 non-renounceable entitlement offer to raise up to approximately $2.2 million at $0.005 per share, a discount of about 20% to its recent volume-weighted average price, with one free attaching option (exercisable at $0.01 for two years) for every two new shares subscribed. Any shortfall from the entitlement offer will be made available under a separate shortfall offer on the same terms, with proceeds earmarked primarily to fund development of lead oncology candidate HMBD-002, including its modular phase II trial, and to support working capital, potentially extending the company’s cash runway and underpinning its clinical development strategy despite the offers not being underwritten.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 new unquoted options as part of a placement or similar capital initiative. The options will have an exercise price of A$0.01 and a two-year term from the issue date, with issuance targeted for April 15, 2026.
The proposed securities issuance signals a move to strengthen Percheron Therapeutics’ capital structure and potential funding flexibility without immediately diluting existing shareholders. By using low‑exercise‑price unquoted options, the company may incentivize stakeholders and align longer-term interests with its future operational and development milestones.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics Limited reported a significantly reduced half-year loss for the period ended 31 December 2025, with net loss after tax falling 64% to $3.1 million from $8.5 million a year earlier. The company held cash reserves of $4.46 million at period end, indicating a moderated cash burn but continued dependence on external funding to support its therapeutic development activities.
Net tangible assets per share declined to 0.66 cents from 1.41 cents, underscoring ongoing balance sheet dilution and asset erosion typical of pre-revenue biotech firms. No dividends were paid or declared for the current or prior corresponding periods, consistent with the company’s focus on reinvestment in research and development rather than shareholder cash returns.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has reported final data from a completed phase I clinical trial of its lead candidate HMBD-002, showing a favourable safety profile with few severe treatment-related adverse events and early signs of anti-tumour activity, including tumour shrinkage and prolonged stable disease in heavily pre-treated metastatic cancer patients. Building on these results, the company has released the design of an adaptive, modular phase II trial that will test HMBD-002 across several tumour types, starting with triple-negative breast cancer, EGFR‑mutant non-small-cell lung cancer, HER2‑negative oesophageal cancer and endometrial cancer, aiming to generate frequent data read-outs while managing risk across multiple study arms; manufacturing of new drug substance for phase II is underway and remains the responsibility of licensor Hummingbird Bioscience, supporting Percheron’s capital-efficient progression into the next stage of clinical development.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
Percheron Therapeutics has disclosed a change in director Ben Gil Price’s holdings, following his on-market purchase of 2 million fully paid ordinary shares on 22 December 2025 for approximately A$17,220, increasing his total shareholding to 7,999,805 shares while his options position remains unchanged. The transaction, which did not occur during a closed period and involved no change in contractual interests, signals increased financial alignment between the director and shareholders and provides additional transparency to investors regarding insider confidence in the company’s prospects.
Percheron Therapeutics has disclosed that director James Garner increased his direct holding in the company by purchasing 1 million fully paid ordinary shares on-market between 17 and 19 December 2025 for a total consideration of $8,500. Following the transaction, Garner holds 53.5 million ordinary shares along with a substantial portfolio of unquoted options, a move that signals continued insider confidence and may be closely watched by shareholders and market participants as an indicator of management’s outlook on the company’s prospects.